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Abstract
Background: In the central nervous system, glial cells provide metabolic and trophic support to neurons and
respond to protracted stress and insults by up-regulating inflammatory processes. Reactive astrocytes and microglia
are associated with the pathophysiology of neuronal injury, neurodegenerative diseases and major depression, in
both animal models and human brains. Several studies have reported clear anti-inflammatory effects of anti-depressant
treatment on astrocytes, especially in models of neurological disorders. Trazodone (TDZ) is a triazolopyridine derivative
that is structurally unrelated to other major classes of antidepressants. Although the molecular mechanisms of TDZ in
neurons have been investigated, it is unclear whether astrocytes are also a TDZ target.
Methods: The effects of TDZ on human astrocytes were investigated in physiological conditions and following
inflammatory insult with lipopolysaccharide (LPS) and tumour necrosis factor-α (TNF-α). Astrocytes were assessed for
their responses to pro-inflammatory mediators and cytokines, and the receptors and signalling pathways involved in
TDZ-mediated effects were evaluated.
Results: TDZ had no effect on cell proliferation, but it decreased pro-inflammatory mediator release and modulated
trophic and transcription factor mRNA expression. Following TDZ treatment, the AKT pathway was activated, whereas
extracellular signal-regulated kinase and c-Jun NH2-terminal kinase were inhibited. Most importantly, a 72-h TDZ
pre-treatment before inflammatory insult completely reversed the anti-proliferative effects induced by LPS-TNF-α. The
expression or the activity of inflammatory mediators, including interleukin-6, c-Jun NH2-terminal kinase and nuclear
factor κB, were also reduced. Furthermore, TDZ affected astrocyte metabolic support to neurons by counteracting the
inflammation-mediated lactate decrease. Finally, TDZ protected neuronal-like cells against neurotoxicity mediated by
activated astrocytes. These effects mainly involved an activation of 5-HT1A and an antagonism at 5-HT2A/C serotonin
receptors. Fluoxetine, used in parallel, showed similar final effects nevertheless it activates different receptors/
intracellular pathways.
Conclusions: Altogether, our results demonstrated that TDZ directly acts on astrocytes by regulating intracellular
signalling pathways and increasing specific astrocyte-derived neurotrophic factor expression and lactate release. TDZ
may contribute to neuronal support by normalizing trophic and metabolic support during neuroinflammation, which is
associated with neurological diseases, including major depression.
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Background
Neuroinflammation constitutes an immune response
against a diverse spectrum of noxious insults in the cen-
tral nervous system (CNS), including pathogen invasion,
tissue damage, and neurodegenerative processes [1].
Astrocytes are the primary glial cell type in the brain
and maintain CNS homeostasis; they promptly respond
to injury and regulate neuroinflammatory events [2–4]
and are therefore promising targets for modulating
neuroinflammation. Both in vitro and in vivo studies
have shown that astrocytes produce various cytokines,
neurotrophic and growth factors [5–8]. Glial cell over-
activation can lead to cytokine-mediated neuronal cell
death [9–11], causing neuropathological changes in CNS
diseases, such as multiple sclerosis [12], Parkinson’s and
Alzheimer’s diseases [13, 14]. Because CNS inflammation
is strongly associated with the pathophysiology of depres-
sion [15], it is not surprising that astrocyte dysfunction
has also been implicated in the neuropathology of major
depression. Post-mortem studies of depressed patients
revealed reduced numbers and altered morphology of glial
cells in cortical regions [16, 17], accompanied by a reduc-
tion of astrocytic markers [18, 19]. Furthermore, preclin-
ical studies have shown that glial cell loss in the rat
prefrontal cortex is sufficient to induce depressive-like
behaviours [20].
Several studies have reported that anti-depressant
treatment of glial cells had anti-inflammatory effects,
especially under conditions that modelled neurological
disorders [21–23]. For example, the commonly used se-
lective serotonin reuptake inhibitor (SSRI) fluoxetine
(FLUOX) counteracts astrocytic cell loss in an animal
model of depression [24]. Moreover, FLUOX reduces
astrocyte glycogen levels and increases glucose
utilization and lactate release [25], providing essential
energy substrates for neurons to sustain normal function
and cellular integrity [26].
Trazodone (TDZ) is a triazolopyridine derivative that is
structurally unrelated to other major classes of antidepres-
sants. Its mechanism of action against depression has not
been fully elucidated, largely in part to its affinity for several
receptors that may contribute to its clinical actions. Unlike
SSRIs, TDZ simultaneously inhibits serotonin transporter
(SERT), while acting as a partial serotonin 5-HT1A receptor
(5-HTR) agonist and a 5-HT2AR and 5-HT2CR antagonists
[27, 28]. Moreover, TDZ exerts antagonistic properties
against α1- and α2-adrenergic receptors (α-AR) and
histamine H1 receptors with minimal anticholinergic
effects [27, 28].
Whereas the molecular and intracellular mechanisms
of TDZ have been investigated in neuronal-like cells and
animal models [29–31], it is unclear whether astrocytes
are a TDZ target. In this study, the effects of TDZ on
human astrocytes were investigated by assessing cellular
proliferation, cytokine release and trophic and pro-
survival gene expression induction. Furthermore, lactate
release was investigated to dissect the contribution of
TDZ to astrocyte metabolic support of neurons. The
intracellular pathways and receptor targets involved
in TDZ-elicited effects were investigated; the study
was carried out not only under physiological condi-
tions, but also following inflammatory insult with




Human astrocytes were purchased from GIBCO (Life
Technologies, Milan, Italy). ELISA kits for cytokines’
determination were from Thermo Fisher Scientific,
Rodano, Milan, Italy. All other reagents were obtained
from standard commercial sources and were of the
highest commercially available grade.
Cell culture, pharmacological treatments and induction of
inflammation
Human astrocytes were cultured in complete medium con-
sisting of DMEM, 1 % N-2 Supplement (Life Technologies,
Milan, Italy), 10 % fetal bovine serum (FBS), and
2 mM L-glutamine, at 37 °C in 5 % CO2. H9-derived
human neural stem cells (NSCs) were purchased from
GIBCO (Life Technologies, Milan, Italy). For neuronal dif-
ferentiation, H9-derived NSCs were plated on polyornithine
and laminin-coated culture dishes, and switched into a de-
fined Neurobasal serum-free medium, containing 2 % B-27,
2 mM L-glutamine and 5 μM retinoic acid (RA) up to
7 days, as reported before [29].
To set up the inflammation model, human astrocytes
were incubated for 2, 6 or 24 h with LPS (50 μg/ml)
and/or TNF-α (50 ng/ml), commonly used as inflamma-
tion inductors [33–35].
Cell proliferation assays
Trazodone (TDZ, Angelini Acraf S.p.a.) was diluted to
different concentrations of stock solutions by saline so-
lution. After replating, human astrocytes (5000 cells/
well) were treated once with different concentrations of
TDZ (1 nM-10 μM), 10 μM fluoxetine (FLUOX) or
10 μM serotonin (5-HT) for 24 or 72 h. To verify the
protective effects of the drugs, human astrocytes were
treated with TDZ, FLUOX or 5-HT for 24 or 72 h; fol-
lowing incubation time, cells were washed and incubated
with LPS-TNF-α for an additional 24 h. In longer treat-
ments (7 days, Additional file 1: Figure S1), drug treat-
ment was repeated every three days.
To dissect the receptor targets involved in TDZ- and
FLUOX-mediated effects, human astrocytes were pre-
treated for 30 min with the following selective receptor
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activators/blockers: 250 nM clonidine (α-adrenergic
agonist, [36]), or 100 μM histamine, or 15 nM (S)-WAY
100135 dihydrochloride (selective 5-HT1AR antagonist
[37]), 10 nM GR 127935 hydrochloride (5-HT1B/DR
antagonist [38]), or 5 nM RS 127445 hydrochloride
(5-HT2BR antagonist [39]), 30 nM (R)-1-(2,5-dimethoxy-
4-iodophenyl)-2-aminopropane [(R)-DOI], (5-HT2A/CR
agonist, [40]), or 100 nM SR 57227 (5-HT3R agonist,
[41]). After pre-incubation, cells were treated with
TDZ (1 nM-10 μM) or 10 μM FLUOX for 72 h,
followed by LPS-TNF-α for an additional 24 h.
At the end of treatments, cell proliferation was deter-
mined using the MTS assay according to manufacturer’s
instruction. Within an experiment, each condition was
assayed in triplicate, and each experiment was performed
at least three times. The results were calculated by sub-
tracting the mean background from the values obtained
from each test condition and were expressed as the per-
centage of the control (untreated cells).
RNA extraction and real-time PCR analysis
Human astrocytes were treated with medium alone
(control), TDZ (100 nM or 1 μM), FLUOX (10 μM) for
24 or 72 h. When indicated, after drug removal, cells
were incubated with LPS-TNF-α for additional 24 h.
When indicated, cells were pre-incubated with 500 nM
Wortmannin (Phosphatidylinositol-4,5-bisphosphate
3-kinase, PI3K, inhibitor) or 5 μM PD98059 (a highly
selective in vitro MEK1 inhibitor, [42]) for 30 min,
before astrocyte treatment with 100 nM TDZ.
At the end of treatments, cells were collected, and total
RNA was extracted using Rneasy® Mini Kit (Qiagen,
Hilden, Germany) according to manufacturer’s instruc-
tions. Purity of the RNA samples was determined by
measuring the absorbance at 260:280 nm. cDNA synthesis
was performed with 500 ng of RNA using i-Script cDNA
synthesis kit (BioRad, Hercules, USA). Primers used for
RT-PCR were designed in intron/exon boundaries to en-
sure that products did not include genomic DNA [29].
RT-PCR reactions consisted of 25 μL Fluocycle® II SYBR®
(Euroclone, Milan, Italy), 1.5 μL of both 10 μM forward
and reverse primers, 3 μL cDNA, and 19 μL of H2O. All
reactions were performed for 40 cycles using the following
temperature profiles: 98 °C for 30 s (initial denaturation);
T °C (see Table 1) for 30 s (annealing); and 72 °C for 3 s
(extension) [29]. β-actin was used as the housekeeping
gene. PCR specificity was determined by both the melting
curve analysis and gel electrophoresis, and the data was
analysed by standard curve method.
Cytokine and lactate release
Human astrocytes were treated with medium alone (con-
trol), TDZ (1 nM-10 μM), FLUOX (10 μM), or 5-HT
(10 μM) for 24 or 72 h. When indicated, after drug
removal, cells were incubated with LPS and TNF-α for an
additional 24 h. The amount of cytokines (i.e., interleukin-
6, IL-6, IL-10 and interferon gamma, IFN-γ) or lactate re-
leased into the culture medium was measured using ELISA
kits (Thermo Fisher Scientific, Rodano, Milan, Italy, and
Sigma Aldrich, Milan, Italy) following the manufacturers’
instructions. Culture supernatants were collected and
stored at −80 °C until assayed for cytokine or lactate
content.
Astrocyte conditioned media
Human H9 NSCs were differentiated to neuronal-like
cells using a defined Neurobasal serum-free medium,
containing 2 % B-27, 2 mM L-glutamine and 5 μM
retinoic acid up to 7 days. Neuronal-like cells were
plated in 96-well plates at a density of 4000 cells per well
and allowed to settle for 24 h at 37 °C before replacement
with conditioned media. Human astrocytes were treated
with medium alone (control), TDZ (1 nM-10 μM),
FLUOX (10 μM) or 5-HT (10 μM) for 24 or 72 h. In some
experiments, after TDZ, FLUOX and 5-HT removal, cells
were incubated with LPS and TNF-α for an additional
24 h. Culture media were collected as conditioned media
and clarified by centrifugation at 20,000×g for 5 min to
Table 1 Nucleotide sequences, annealing temperature and product size of the primers utilised in PCR experiments
Gene Primer nucleotide sequences Product size (base pairs) Annealing temperature
CREB FOR: 5’-AAGCTGAAAGTCAACAAATGACA-3’ 240 52 °C
REV: 5’-CCTCTTTTCAGAAAAATTCAGGA-3’
BDNF FOR: 5’-TACATTTGTATGTTGTGAAGATGTTT-3’ 131 56 °C
REV: 5’- TTACTCGCCCCGGACCCTCT-3’
NF-kB FOR: 5’- GCTCCGGAGACCCCTTCCA-3’ 198 54 °C
REV: 5’- GGTTTGAGGTAGTTTCCCAGT-3’
mTOR FOR: 5’-CCGTTCCATCTCCTTGTCACG-3’ 209 56 °C
REV: 5’-CCACTTACTCTGCAGTGTG-3’
β-actin FOR: 5’-GCACTCTTCCAGCCTTCCTTCC-3’ 254 55 °C
REV-5’-GAGCCGCCGATCCACACG-3’
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remove cellular debris. The media were then transferred
onto neuronal-like cells, whose prolifer+ation was mea-
sured using the MTS assay as described above after 24 h
of incubation (see Fig. 8a).
MAPK (mitogen-activated phosphorylation kinase) assays
Astrocytes were treated with medium alone (control),
TDZ (1 nM-10 μM), or FLUOX (10 μM) or 5-HT
(10 μM), for 30 min or 24 h. In some experiments, be-
fore incubation with TDZ (10 μM) or FLUOX (10 μM),
cells were pre-treated for 15 min with the following se-
lective receptor activators/inhibitors: 250 nM clonidine
(α-adrenergic agonist), or 100 μM histamine, or 15 nM
(S)-WAY 100135 dihydrochloride (selective 5-HTR1AR
antagonist), 10 nM GR 127935 hydrochloride (5-HTR1B/DR
antagonist), or 5 nM RS 127445 hydrochloride (5-HT2BR
antagonist) or 30 nM (R)-DOI (5-HT2A/CR agonist), or
100 nM SR 57227 (5-HT3R agonist). Similarly, human
astrocytes were pre-treated with 1 μM H89 (Protein Kinase
A, PKA inhibitor), or 1 μM bisindolylmaleimide (PKC in-
hibitor), or 500 nM wortmannin (PI3K, inhibitor). Finally,
to block Gαi/o proteins, cells were pre-incubated in non-
complete medium with 200 ng/ml pertussin toxin (PTX)
for 18 h.
When indicated, after TDZ or FLUOX treatment for
24 or 72 h, the drugs were removed, and astrocytes were
incubated with LPS and TNF-α for additional 24 h.
At the end of treatments, cells were fixed with 4 % for-
maldehyde to preserve activation of specific protein
modification. Levels of total and phosphorylated AKT,
c-Jun N-terminal kinases (JNKs) and extracellular
signal-regulated kinases (ERK1/2) were determined by
ELISA assays, as previously reported [29, 43]. Briefly,
the cells were washed three times with wash buffer
(0.1 % Triton X-100 in PBS) and 100 μl of quenching
buffer (1 % H2O2; 0.1 % sodium azide in wash buffer)
was added and incubation was protracted for other
20 min. The cells were washed with PBS twice, and
then 100 μl of blocking solution (1 % BSA; 0.1 % Triton
X-100 in PBS) was added for 60 min. After blocking, cells
were washed three times with wash buffer and the specific
primary antibodies (anti-phospho ERK1/2, 1:500, sc-7383
Santa Cruz Biotechnology; anti-ERK1/2, 1:500, #4695 Cell
Signaling Technology; anti-phospho JNK, 1:500, sc-6254
SantaCruz Biotechnology; anti-JNK, SAB4200176, 1:750,
Sigma Aldrich, Milan, Italy; anti-phospho AKT, 1:500,
sc-7985 Santa Cruz Biotechnology; anti-AKT, 1:1000,
SAB4500799, Sigma Aldrich, Milan, Italy) were added
on at 4 °C. Subsequent incubation with secondary
HRP-conjugated antibodies and developing solution
allowed a colorimetric quantification of total and
phosphorylated levels. Blanks were obtained processing
wells without cells in the absence of the primary antibody.
The relative number of cells in each well was then
determined using Crystal Violet solution. The results were
calculated by subtracting the mean background from the
values obtained from each test condition; values were
normalized to the number of cells in each well, and were
expressed as the percentage of untreated cells (basal).
ERK overexpression
Cells were transfected with human CMV6-XL4 MAPK
(Origene, Rockville, MD, USA) or with the plasmid alone
by the PEI method (JetPEI, Polyplus transfection, [44]).
Two days after transfection, astrocytes were trypsinized
and seeded in medium containing 200 μg/ml ampicillin.
MAPK overexpression was verified by western blot, as
described below.
Western blot analysis
Astrocytes were treated with medium alone (control),
TDZ (1 or 10 μM), or FLUOX (10 μM) or Rapamycin
(RAPA, 15 nM) for 24 or 72 h. At the end of the treat-
ment period, the cells were collected and then were
lysed for 60 min at 4 °C using 200 μL of RIPA buffer
(9.1 mM NaH2PO4, 1.7 mM Na2HPO4, 150 mM NaCl,
pH 7.4, 0.5 % sodium deoxycholate, 1 % Nonidet P-40,
0.1 % SDS, and a protease-inhibitor cocktail). Equal
amounts of the cell extracts (40 μg of protein) were diluted
in Laemmli sample solution, resolved using SDS-PAGE
(8.5 %), transferred to PVDF membranes and probed over-
night at 4 °C using the following primary antibodies: anti-
phospho ERK1/2, 1:500, sc-7383 Santa Cruz Biotechnology;
anti-ERK1/2, 1:1000, #4695 Cell Signaling Technology;
anti-phospho JNK, 1:500, sc-6254 SantaCruz Biotechnol-
ogy; anti-JNK, SAB4200176, 1:750, Sigma Aldrich, Milan,
Italy; anti-phospho AKT, 1:500, sc-7985 Santa Cruz
Biotechnology; anti-AKT, 1:1000, SAB4500799, Sigma
Aldrich, Milan, Italy; anti-microtubule-associated protein
light chain-3 (LC3B, sc-28266 Santa Cruz Biotechnology,
1:100); anti-glial fibrillary acidic protein, GFAP (sc-9065,
Santa Cruz Biotechnology 1:50) and glyceraldehyde-3-
phosphate dehydrogenase, GAPDH (G9545, Sigma
Aldrich, Milan, Italy, 1:5000). The primary antibodies were
detected using the appropriate peroxidase-conjugated
secondary antibodies, which were then detected using a
chemiluminescent substrate (ECL, Perkin Elmer).
Densitometric analysis of the immunoreactive bands
was performed using Image J Software.
NF-κB activation
Human astrocytes were treated with medium alone
(control) or TDZ (1 μM) for 24 or 72 h; after drug re-
moval, cells were incubated with LPS-TNF-α for an
24 h. At the end of treatment, cells were lysed in the
“subcellular fractionation buffer” (250 mM Sucrose,
20 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM
EDTA, 1 mM EGTA, pH 7.4), containing 1 mM DTT
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and protease-inhibitor cocktail. The cells were centri-
fuged at 1,000 x g for 10 min to isolate nuclei, and the
supernatants were centrifuged again at 10,000×g to ob-
tain the cytosolic/membrane fraction. Nuclei were sus-
pended in the subcellular fractionation buffer; the
protein levels of NF-kB p65 were evaluated in cytoplas-
mic and nuclear extracts (40 μg) by western blot ana-
lysis, as described before, using the following primary
antibodies: anti-NF-κB p65, 1:300, sc-372 Santa Cruz
Biotechnology; histone H3 (nuclear marker), 1:500, sc-
10809 Santa Cruz Biotechnology; GAPDH (cytoplas-
matic marker).
CREB activation
Human astrocytes were treated with medium alone
(control), TDZ (1 μM), FLUOX (10 μM) for 24 or 72 h.
After drug removal, cells were incubated with LPS-TNF-
α for additional 24 h. Levels of phosphorylated and total
CREB were detected by the high-throughput TransAM®
assay (Active Motif, La Hulpe, Belgium), following the
manufacturer’s instructions.
Statistical analysis
The nonlinear multipurpose curve-fitting program
Graph-Pad Prism (GraphPad Software Inc., San Diego,
CA) was used for data analysis and graphic presenta-
tions. All data are presented as the mean ± SEM. Statis-
tical analysis was performed by one-way analysis of
variance (ANOVA) with Tukey HSD corrected t test for
post hoc pair-wise comparisons. P < 0.05 was considered
statistically significant.
Results
Effect of TDZ treatment on astrocyte proliferation
To verify whether TDZ treatment affected astrocyte pro-
liferation, human cells were treated with different con-
centrations of the drug (1 nM-10 μM) for 24 or 72 h. As
shown in Fig. 1a, b, 24 and 72 h of TDZ incubation did
not induce any significant changes in astrocyte prolifera-
tion at any concentration tested. Similar results were ob-
tained with FLUOX or 5-HT (Fig. 1a, b).
The effects of TDZ treatment on glial inflammation
were then investigated. To activate astrocytes, cells were
treated with 50 μg/ml LPS and 50 ng/ml TNF-α for vari-
ous time periods. Whereas no significant reduction in
astrocyte proliferation was observed within 16 h of in-
flammatory insult (Fig. 1c), LPS-TNF-α challenge for
24 h decreased the percentage of viable/proliferative as-
trocytes to 43.7 ± 3.3 % (Fig. 1c). Therefore, the latter
condition was chosen for the experimental model of in
vitro astrocyte activation.
Upon 24 h TDZ, FLUOX or 5-HT pre-treatment be-
fore inflammatory insult induction, a significant increase
in proliferation at all concentrations examined was
observed (Fig. 1d). Similar results were obtained when
cells were pre-treated for 72 h (Fig. 1e). These results
suggest that TDZ exerts cyto-protective effects on
human astrocytes in an experimental model of
inflammation.
Effect of TDZ treatment on cytokine release
To evaluate the effect of TDZ on astrocyte cytokine pro-
duction, pro- (i.e. IL-6 and IFN-γ) and anti-
inflammatory (i.e. IL-10) cytokine release were analysed.
Astrocytes were challenged with LPS-TNF-α for 24 h in
the presence or absence of drug pre-treatment.
At all concentrations tested, TDZ, FLUOX or 5-HT
alone did not markedly alter IL-6, IFN-γ or IL-10 release
after 24 h of treatment (Fig. 2a, c, e). In contrast, 72-h
TDZ treatment significantly reduced IFN-γ release, with-
out altering IL-6 or IL-10 production (Fig. 2b, d, f ).
Similar results were obtained upon cell treatment with
FLUOX and 5-HT (Fig. 2b, d, f ).
As expected, inflammatory insult (LPS-TNF-α) signifi-
cantly elevated IL-6 and IFN-γ levels and reduced basal
IL-10 release (Fig. 3a–f ), consistent with previous re-
ports [7, 45].
Astrocyte challenge with micromolar concentrations
of TDZ for 24 h before inflammatory damage signifi-
cantly prevented IL-6 release (Fig. 3a). Moreover, a trend
toward IFN-γ reduction (Fig. 3c) and IL-10 increase
(Fig. 3e) was evidenced.
After 72 h pre-treatment, IFN-γ release was signifi-
cantly prevented at all concentrations tested (Fig. 3d).
Moreover, TDZ counteracted the LPS-TNF-α-induced
decrease in IL-10 levels at a range of concentrations be-
tween 500 nM and 10 μM (Fig. 3f ).
In a similar manner, FLUOX and 5-HT prevented IL-6
release after 24 h (Fig. 3a), while they reduced IFN-γ re-
lease (Fig. 3d) and counteracted IL-10 reduction (Fig. 3f )
in astrocytes pre-incubated for 72 h. These data may
suggest that IL-6 is involved in the 24-h pre-treatment
before induction of inflammation, while IFN-γ and IL-10
can play major roles in a longer pre-treatment with anti-
depressant drugs.
Taken together, these results demonstrate that TDZ
pre-treatment of human astrocytes, particularly for 72 h,
reduced pro-inflammatory cytokine release and counter-
acted the reduction in anti-inflammatory cytokine
release.
Effect of TDZ treatment on pro-inflammatory gene,
trophic factor and transcription factor expression
Nuclear factor kappa B (NF-κB) is a crucial regulator of
immunity and inflammation and has been shown to be
pivotal for astrocytic neuroinflammatory responses [46].
Therefore, the effects of TDZ treatment on NF-kB ex-
pression were analysed in the absence and presence of
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astrocyte activation with LPS-TNF-α. In parallel, the ex-
pression of trophic and transcription factors was
investigated.
After 24 h of TDZ treatment, a significant up-
regulation of the mRNA levels of brain-derived nerve
factor (BDNF) and the cAMP response element-binding
protein (CREB) was observed (Fig. 4a), suggesting that
TDZ alone induced the expression trophic and tran-
scription factors. In contrast, the pro-inflammatory gene
NF-kB and mammalian target of rapamycin (mTOR)
mRNA levels significantly decreased (Fig. 4a). These re-
sults confirmed the anti-inflammatory effect of TDZ, as
mTOR inhibition has been demonstrated to elicit anti-





Fig. 1 (See legend on next page.)
Daniele et al. Journal of Neuroinflammation  (2015) 12:225 Page 6 of 24
As a comparison, astrocyte incubation with FLUOX
showed similar results both after 24 or 72 h of cell treat-
ment: the SSRI enhanced CREB, BDNF and mTOR
mRNA levels, without significantly altering NF-kB
transcription (Fig. 4a, b). These data are consistent with
previous reports on the SSRI drug [25]. Surprisingly, a
72-h TDZ challenge had opposite effects; it significantly
increased NF-kB and mTOR mRNA levels and reduced
CREB transcription (Fig. 4b).
To dissect if a long term treatment with the anti-
depressant could activate astrocytes, the levels of the
astrocyte-specific activation marker GFAP were measured.
Western blot analysis did not show any significant in-
crease of GFAP in TDZ-treated samples (Fig. 4c, d).
Consistent with these data, astrocyte proliferation was not
affected even after 7 days of TDZ treatment (Additional
file 1: Figure S1).
The effects of the inflammatory damage on the expres-
sion of trophic and transcription factors were then
determined. LPS-TNF-α treatment significantly in-
creased NF-kB levels (Fig. 5a), consistent with its role as
a pro-inflammatory gene [46]. Moreover, mTOR and
CREB levels were significantly increased (Fig. 5a). These
results are consistent with previous data from LPS or
TNF-α-stimulated glial cells [48, 49]. Pre-incubation of
astrocytes with TDZ or FLUOX for 24 h further in-
creased inflammation-mediated increase in NF-kB
mRNA expression, suggesting that 24-h pre-treatment
with antidepressants is not sufficient to reverse the effects
of LPS-TNF-α on NF-kB induction. In contrast, a signifi-
cant decrease in mTOR levels after 24-h TDZ pre-
incubation was evidenced (Fig. 5b).
TDZ treatment for 72 h significantly counteracted the
LPS-TNF-α-induced increase in NF-kB, CREB and
mTOR expression (Fig. 5c). Α decrease in BDNF expres-
sion was also observed. Similar results were observed
upon FLUOX treatment (Fig. 5c). These data demon-
strate that TDZ pre-incubation for 72 h counteracts the
induction of the pro-inflammatory genes mediated by
LPS-TNF-α.
Following stimuli that elicit the NF-kB pathway, its
transcription factor subunits, p65 and p50, expose
nuclear targeting signals and then translocate into the
nucleus [50]. Consistent with real-time PCR data, LPS-
TNF-α induced a significant p65 nuclear accumulation
(Fig. 6a, b); astrocyte pre-treatment for 72 h with TDZ
(1 μM) significantly counteracted LPS-TNF-α-mediated
NF-kB activation (Fig. 6a, b).
ELISA experiments showed that the inflammatory
stimuli caused CREB phosphorylation (Fig. 6c), consistent
with literature [49] and real-time PCR data (Fig. 5a).
Astrocyte pre-treatment for 72 h with TDZ or FLUOX
significantly decreased CREB activation induced by LPS-
TNF-α (Fig. 6c). Globally, these data confirmed that TDZ
pre-incubation for 72 h counteracts the induction of the
pro-inflammatory mediators elicited by LPS-TNF-α.
Effect of TDZ treatment on the autophagic pathway
Given recent publications on the link between antide-
pressants and autophagy [51, 52], and the modulation of
mTOR mRNA in TDZ-treated samples, the effects of
TDZ on astrocytic autophagy was verified. During the
autophagic process, the microtubule-associated protein
light chain-3 (LC3B-I) becomes conjugated with phos-
phatidyl ethanolamine to form LC3B-II that integrates
into the autophagosomal membrane [53]. In astrocytes
treated with TDZ or FLUOX for 24 or 72 h, any signifi-
cant LC3B-I-to-LC3B-II conversion indicative of
autophagosome formation was evidenced (Fig. 6d, e),
as compared with the standard mTOR inhibitor rapamycin
[54]. These data demonstrate that neither TDZ nor FLUOX
affect autophagy pathways in human astrocytes.
Consistent with our data, selective SSRIs have been
demonstrated to not induce autophagy [52], while in a
different paper, the SSRI paroxetine has been reported
to cause cell autophagy in mice and human cells [55].
Effects of TDZ treatments on lactate release
In addition to supplying neurotrophic/growth factors,
astrocytes provide essential energy substrates to neurons.
In particular, astrocytes take up glucose and
glycolytically metabolize it to lactate, which is then re-
leased in the extracellular space and oxidized by neurons
to meet part of their energy needs [56]. These observa-
tions led us to examine whether TDZ alters lactate re-
lease from human astrocytes.
(See figure on previous page.)
Fig. 1 Effect of TDZ on astrocyte proliferation and on an experimental inflammation model. a, b Human astrocytes were treated with medium
alone (control), or different concentrations of TDZ (1 nM-10 μM), or FLUOX (10 μM) or 5-HT (10 μM) for 24 h (a) or 72 h (b). At the end of the
treatments, cell proliferation was measured by MTS assay. The data are expressed as percentages relative to untreated cells (control), which were
set at 100 %, and represent the mean ± SEM of three independent experiments, each performed in triplicate. Statistical significance was determined
using a one-way ANOVA-Tukey HSD post hoc test. c Human astrocytes were treated with 50 μg/ml LPS and 50 ng/ml TNF-α for different time periods
(2–24 h). d, e Human astrocytes were treated with different concentrations of TDZ (1 nM-10 μM), or FLUOX (10 μM) or 5-HT (10 μM) for 24 h (d) or
72 h (e); after drug removal, cells were incubated with 50 μg/ml LPS and 50 ng/ml TNF-α for an additional 24 h. At the end of treatment, cell proliferation
was measured by MTS assay. The data are expressed as percentages relative to untreated cells (control), which were set at 100 %, and represent the mean
± SEM of three independent experiments, each performed in triplicate. Statistical significance was determined using a one-way ANOVA-Tukey HSD post
hoc test: **P< 0.001, ***P< 0.001 vs. control; ##P< 0.01, ###P< 0.001 vs. cells treated with LPS-TNF-α
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As shown in Fig. 7a, TDZ treatment for 72 h signifi-
cantly increased lactate release; the same was not
observed for the 24-h treatment. Similar results were
obtained in the presence of FLUOX, but not of the en-
dogenous transmitter 5-HT (Fig. 7a).
Interestingly, LPS-TNF-α significantly decreased the
amount of lactate in the culture media (Fig. 7b). TDZ or
FLUOX treatment for 24 h before inflammation induction
did not affect the inflammation-induced decrease in
lactate (Fig. 7b), confirming that a 24-h incubation with
anti-depressant is not sufficient to induce significant
changes in astrocyte metabolism. In contrast, drug pre-
treatment for 72 h completely reversed the LPS-TNF-α-
induced decrease in lactate release (Fig. 7b), suggesting





Fig. 2 Effect of TDZ on cytokine release. Human astrocytes were treated with different concentrations of TDZ (1 nM-10 μM), or FLUOX (10 μM) or 5-HT
(10 μM) for 24 h (a, c, e) or 72 h (b, d, f). At the end of treatment, culture supernatants were collected, and the amounts of IL-6 (a, b), IFN-γ (c, d) and
IL-10 (e, f) released were measured using ELISA kits following the manufacturer’s instructions. The data are expressed as percentages relative to untreated
cells (control), which were set at 100 %, and represent the mean ± SEM of two independent experiments, each performed in duplicate. Statistical
significance was determined using a one-way ANOVA-Tukey HSD post hoc test: *P< 0.05, **P< 0.01, ***P< 0.001 vs. control
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Effects of TDZ on astrocyte-mediated neurotoxicity
Reactive astrocytes can induce neuronal cell degeneration
by releasing inflammatory mediators and cytokines [57].
We, therefore, investigated whether TDZ contributes to the
relief of activated astrocyte-induced neurotoxicity (Fig. 8a).
As shown in Fig. 8b, conditioned media from 24 or
72 h 5-HT-, FLUOX- or TDZ-treated astrocytes did
not significantly affect neuronal-like cell proliferation.
In contrast, conditioned media from LPS-TNF-α-stim-
ulated astrocytes significantly decreased neuronal-like
cell proliferation (Fig. 8c). Upon 24 or 72 h TDZ pre-
treatment prior to LPS-TNF-α stimulation (Fig. 8c),
LPS-TNF-α-induced effects were significantly counter-




Fig. 3 Cytokine release in an experimental model of inflammation. Human astrocytes were treated with medium alone (control), or different
concentrations of TDZ (1 nM-10 μM), or FLUOX (10 μM) or 5-HT (10 μM) for 24 h (a, c, e) or 72 h (b, d, f); after drug removal, cells were incubated
with 50 μg/ml LPS and 50 ng/ml TNF-α for an additional 24 h. At the end of treatments, supernatants were collected, and the amounts of IL-6
(a, b), IFN-γ (c, d) and IL-10 (e, f) were measured using ELISA kits following the manufacturer’s instructions. The data are expressed as percentages
relative to untreated cells (control), which were set at 100 %, and represent the mean ± SEM of two independent experiments, each performed in
duplicate. Statistical significance was determined using a one-way ANOVA-Tukey HSD post hoc test: *P < 0.05, **P < 0.01, ***P < 0.001 vs. control;
#P < 0.05, ##P < 0.01, ###P < 0.001 vs. LPS-TNF-α-treated cells
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in a minor extent, with 5-HT (Fig. 8c), suggesting
that the two antidepressants suppress neurotoxicity
mediated by activated astrocytes.
Contributions of the 5-HT receptors to TDZ pro-survival
effects
To dissect the putative contribution of 5-HT receptors
to the protective effects elicited by TDZ, viability experi-
ments were repeated in the presence of the selective 5-HT
serotonin receptor agonists/antagonists. Because SERT is
not expressed on astrocytes [58], the experiments were
performed considering TDZ agonism at 5-HT1AR and its
antagonism at 5-HT2A/CRs, α-adrenergic and H1 histamine
receptors [27, 28]. In contrast, FLUOX, despite the general
thought to owe its therapeutic potency to SERT inhibition,
has shown relatively high affinity the 5-HT2BR in cultured
astrocytes [58]; moreover, FLUOX also binds 5-HT1A/B/DRs
and antagonises 5-HT2A/CRs and 5-HT3Rs [59, 60].
Fig. 4 Effect of TDZ on pro-inflammatory gene, trophic and transcription factor expression. a, b Human astrocytes were treated with medium
alone (control), or different concentrations of TDZ (100 nM-1 μM) or FLUOX (10 μM) for 24 h (a) or 72 h (b). At the end of treatment, total RNA
was extracted, and relative mRNA quantification of NF-kB, CREB, mTOR and BDNF was performed by real-time RT-PCR. The data are expressed as
fold changes vs. control and represent the mean ± SEM of three different experiments, each performed in duplicate. Statistical significance was
determined using a one-way ANOVA-Tukey HSD post hoc test: *P < 0.05, **P < 0.01, ***P < 0.001 vs. control. c, d Human astrocytes were treated
with medium alone (control), TDZ (10 μM) or FLUOX (10 μM) for 72 h. Following incubation, the protein levels of GFAP were evaluated by western blot
analysis. GAPDH was the loading control. c Representative western blots. d Densitometric analysis of the immunoreactive bands was performed using
ImageJ. The data are expressed as the percentage of optical density of the immunoreactive band relative to that of the control, which was set at 100 %,
and are the mean values ± SEM of three different experiments. Statistical significance was determined using a one-way ANOVA-Tukey HSD post hoc test
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The results (Fig. 9a) demonstrated that TDZ failed to
reverse LPS-TNF-α-mediated decrease of cell prolifera-
tion in the presence of the 5HT-1AR antagonist WAY
100135 or of 5-HT2A/CR agonist R-DOI. Notably,
FLUOX mainly exerted its protective effects through the
activation of the 5-HT2BR subtype, as demonstrated by
the lack of FLUOX-mediated effects in the presence of
the selective 5-HT2BR antagonist RS-12787445 (Fig. 9b).
FLUOX protective effects appeared to be partially medi-
ated by the block of 5HT-2A/CRs (Fig. 9b). Globally,
these data demonstrate that the two anti-depressant
drugs exert cyto-protective actions involving different
5-HTR subtypes.
Intracellular pathways associated with TDZ-mediated
effects in physiological conditions
The possible intracellular cascades, as the basis of the
effects elicited by TDZ, were then investigated.
MAPKs have important roles in modulating pro-
inflammatory cytokine expression in activated astro-
cytes and are a common target in glial cells for many
of the currently used pharmacological treatments for
depression [57, 61–63]. Therefore, the effects of TDZ
on the activities of ERK1/2, AKT and JNK in human
astrocytes were investigated.
ERK 1/2
Challenging cells with FLUOX significantly increased p-
ERK (Fig. 10a), consistent with previous reports on the
SSRI [64]. Surprisingly, TDZ significantly decreased p-
ERK/T-ERK ratio in a concentration-dependent manner
after 30 min (Fig. 10a). The concentration-dependence
was lost in longer treatment (24 h, Fig. 10b), and TDZ
significantly decreased basal ERK activation at 1 nM and
10 μM. These data were confirmed by western blot ex-
periments (Additional file 2: Figure S2).
Selected experiments were then performed to shed
light on TDZ-receptor targets and second messengers




Fig. 5 Expression of pro-inflammatory genes, trophic and transcription
factors in an experimental model of inflammation. a Human astrocytes
were treated with 50 μg/ml LPS and 50 ng/ml TNF-α for 24 h. b, c
Human astrocytes were treated with medium alone (control),
different concentrations of TDZ (100 nM-1 μM), or FLUOX (10 μM)
for 24 h (b) or 72 h (c); after drug removal, cells were incubated
with 50 μg/ml LPS and 50 ng/ml TNF-α for an additional 24 h. At
the end of treatment, total RNA was extracted, and relative mRNA
quantification of NF-kB, CREB, mTOR and BDNF was performed by
RT-PCR. The data are expressed as fold changes vs. control and
represent the mean ± SEM of three different experiments, each
performed in duplicate. Statistical significance was determined
using a one-way ANOVA-Tukey HSD post hoc test: *P < 0.05,
**P < 0.01, ***P < 0.001 vs. control; #P < 0.05, ##P < 0.01, ###P < 0.001
vs. cells treated with LPS-TNF-α
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Pre-treating cells with WAY 100135 or R-DOI coun-
teracted the decrease in ERK phosphorylation elicited by
TDZ (Fig. 10c); marginal and not significant effects were
noticed in the presence of α-adrenergic agonist clonidine
or of histamine (Fig. 10c). These results demonstrate
that TDZ-mediated effects on ERKs mainly involved
the activation of 5TH1AR and the antagonism at 5-
HT2A/CRs. In contrast, FLUOX-mediated ERK activa-
tion returned to basal value in the presence of the
5HT-2BR antagonist RS-127445 (Fig. 10d).
Fig. 6 Effect of TDZ on NF-kB /CREB activation and on the autophagic pathway. a, b Human astrocytes were treated with medium alone or TDZ
(1 μM) for 24 or 72 h, and then with LPS-TNF-α for an additional 24 h. NF-kB p65 protein levels were evaluated in cytoplasm and nuclei by
western blot analysis. GAPDH and H3 were the loading controls. a Representative western blots. b Densitometric analysis of the immunoreactive
bands was performed using ImageJ. The data are expressed as the percentage of optical density of the immunoreactive band relative to that of
the control, which was set at 100 % and are the mean values ± SEM of three different experiments. c Human astrocytes were treated with
medium alone, or TDZ (1 μM) or FLUOX (10 μM) for 24 h or 72 h, and then with LPS-TNF-α for an additional 24 h. At the end of treatment, CREB
activation was determined by ELISA, as described in the Methods section. The data are expressed as percentages relative to untreated cells
(control), which were set at 100 %, and represent the mean ± SEM of two independent experiments, each performed in duplicate. d, e Human
astrocytes were treated with medium alone, TDZ or FLUOX or Rapamycin (RAPA) for 24 or 72 h. Following incubation, the protein levels of LC3B were
evaluated by western blot analysis. GAPDH was the loading control. d Representative western blots. e Densitometric analysis of the immunoreactive
bands. The data are expressed as the percentage of optical density of the immunoreactive band relative to that of the control, which was set at 100 %,
and are the mean values ± SEM of three different experiments. Statistical significance was determined using a one-way ANOVA-Tukey HSD post hoc
test: **P < 0.01, ***P < 0.001 vs. control; ##P < 0.01, ###P < 0.001 vs. cells treated with LPS-TNF-α
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Consistent with 5HT-2BR coupling to second messen-
gers, we found that FLUOX-elicited effects on ERK 1/2
were sensitive to cell pre-incubation with PI3K, PKA
and PKC inhibitors (Fig. 10e), whereas ERK inhibition
by TDZ was blocked in the presence of PTX, thus dem-
onstrating the involvement of Gαi/o proteins (Fig. 10e).
The TDZ-mediated decrease of ERK activity within
24 h of treatment suggests that this anti-depressant
activates CREB and BDNF transcription (Fig. 4a) via a
different, ERK-independent, mechanism. Consistent with
this hypothesis, TDZ enhancement of CREB and BDNF
mRNA levels was counteracted by the PI3K inhibitor
wortmannin (Additional file 3: Figure S3).
AKT
ELISA and western blot experiments showed that TDZ
induced a concentration-dependent significant AKT acti-
vation at 30 min of incubation (Fig. 11a, Additional file
4: Figure S4), thus confirming the involvement of PI3K/
AKT pathway in TDZ-elicited effects. Phosphorylation
was not evidenced in longer treatment (24 h, Fig. 11b).
TDZ-mediated AKT phosphorylation appeared to be sen-
sitive to cell pre-incubation with both 5-HT1AR antagonist
and α-AR agonist (Fig. 11c); moreover, AKT signalling
involved Gαi proteins, as well as PI3K and PKA (Fig. 11e).
As a comparison, FLUOX induced AKT activation
both after 30 min and 24 h of astrocyte incubation
(Fig. 11a, b, Additional file 4: Figure S4), consistent with
previous data [65]. FLUOX-elicited effects mainly in-
volved 5HT2BR, and in a minor way the 5HT1B/DR sub-
types (Fig. 11d), depending from PI3K, PKA and PKC
signalling proteins (Fig. 11e).
JNK
ELISA assays showed that TDZ or FLUOX alone signifi-
cantly affected phosphorylated/total JNK levels in astro-
cytes incubated within 30 min of cell treatment
(Fig. 12a). These data were confirmed by western blot
(Additional file 5: Figure S5) and globally suggest that
JNK inhibition may be involved in the TDZ-induced ef-
fects in astrocytes under physiological conditions. The
effects were almost completely lost in longer treatment
(24 h, Fig. 12b).
The use of selective agonists/antagonists of 5HT-Rs
allowed demonstrating that TDZ-mediated effects on
JNK activation mainly involved drug activation of 5-
TH1AR (Fig. 12c). Interestingly, α-AR receptors appeared
to contribute to JNK inhibition too (Fig. 12c). In con-
trast, FLUOX-elicited effects on JNK pathway were
mediated by 5-TH1ARs and 5-TH2BRs (Fig. 12d).
JNK inhibition by both FLUOX and TDZ appeared to
be sensitive to both PKC and PI3K inhibitors (Fig. 12e).
Intracellular pathways associated with TDZ-mediated ef-
fects under inflammatory insult
LPS-TNF-α stimulation enhanced phosphorylated/total
ERK (Fig. 13a, b) and JNK (Fig. 13c, d) ratio, thus confirm-
ing the latter’s role in astrocyte inflammation [66, 67].
TDZ pre-treatment for 24 h (Fig. 13a) or 72 h (Fig. 13b)
still decreased ERK activation. Consistent with these data,
a
b
Fig. 7 Effect of TDZ on lactate release. a Human astrocytes were
treated with medium alone (control), or TDZ (10 μM), or FLUOX
(10 μM) or 5-HT (10 μM) for 24 or 72 h. b Cells were treated as in a.
After drug removal, cells were incubated with LPS-TNF-α for additional
24 h. At the end of treatment, supernatants were collected, and
the amounts of lactate released were measured using an ELISA kit
according to the manufacturer’s instructions. The data are
expressed as percentages relative to untreated cells (control),
which were set at 100 %, and represent the mean ± SEM of two
independent experiments, each performed in duplicate. Statistical
significance was determined using a one-way ANOVA followed by
a Bonferroni post-test: *P < 0.05, **P < 0.01, ***P < 0.001 vs. control;
#P < 0.05 vs. cells treated with LPS-TNF-α
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following ERK overexpression (Additional file 6: Fig S6 A
and B), TDZ-mediated ERK inhibition were completely
abolished (Additional file 7: Fig S7).
Moreover, TDZ counteracted the LPS-TNF-α-induced
increase in phosphorylated JNK levels after both 24 h
(Fig. 13c) and 72 h (Fig. 13d). These results suggest that
the protective effects of TDZ against reactive astrocytes
at least partially involve the JNK pathway.
Discussion
In the present paper, TDZ was demonstrated to directly
affect human astrocytes in vitro under physiological con-
ditions and following inflammatory insult. TDZ is a
triazolopyridine derivative, which is structurally unre-
lated to other major classes of antidepressants; its mo-
lecular and intracellular mechanisms have been
investigated in neuronal-like cells and in animal models
[29–31]. This is the first study to examine the direct ef-
fects of TDZ on astrocytes, both under physiological
conditions and inflammation.
Under physiological conditions TDZ significantly up-
regulated BDNF and CREB after 24 h, consistent with
data obtained with FLUOX or those previously reported
for SSRIs in primary cortical astrocyte cultures [25], thus
confirming that these factors may contribute to the
therapeutic action of anti-depressant drugs also in
Fig. 8 Effects of TDZ on astrocyte-mediated neurotoxicity. a, b, c Human astrocytes were first treated with the indicated concentrations of TDZ,
FLUOX or 5-HT for 24 or 72 h (b); after TDZ removal, cells were incubated with LPS-TNF-α for an additional 24 h (c). At the end of treatment, the
media were collected as conditioned media and added to neuronal-like cells for 24 h. a Scheme of treatment. b, c Neuronal-like cell proliferation
was measured by MTS assay. The data are expressed as percentages relative to untreated cells (control), which were set at 100 %, and represent
the mean ± SEM of three independent experiments, each performed in triplicate. Statistical significance was determined using a one-way ANOVA
followed by a Bonferroni post-test: **P < 0.01 vs. control; #P < 0.05, ##P < 0.01 vs. cells treated with LPS-TNF-α
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astrocytes. Surprisingly, a 72-h TDZ challenge signifi-
cantly increased NF-kB mRNA levels and reduced CREB
levels, suggesting astrocytic activation similar to what
has been proposed for other antidepressants [68]. Actu-
ally, TDZ did not affect astrocyte viability, even after
7 days of incubation. Moreover, TDZ did not modulate
the levels of the astrocyte-specific activation marker,
GFAP, and did not affect autophagy pathways, thus
suggesting that this anti-depressant does not activate
astrocytes. Autophagy induction elicited by amitriptyline
and the SSRI citalopram [52] was indeed associated with
a decrease of neuronal and glial viability.
The effects of TDZ were then tested in an in vitro in-
flammatory model, established using LPS and TNF-α,
which mimics the stress-related changes in trophic and
pro-inflammatory genes [69, 70]. When astrocytes were
pre-treated with TDZ for 72 h before inflammatory
insult, cell proliferation and pro- and anti-inflammatory
cytokine levels were rescued to control levels, as previ-
ously shown in neuronal cells [29] and for other antide-
pressants, including FLUOX, in glial cells [32, 33].
Moreover, similarly to what observed with FLUOX, TDZ
significantly counteracted the LPS-TNF-α-induced
mRNA expression of NF-kB, CREB and mTOR. ELISA
and western blot analyses confirmed a reduction in NF-
kB and CREB activation upon cell pre-treatment with
TDZ for 72 h. Consistent with our data, mTOR inhib-
ition has been demonstrated to elicit anti-inflammatory
effects in glial cells [47], while beneficial roles of NF-κB
inhibition through alteration of the inflammatory envir-
onment have been shown [71].
Of note, the effects elicited by TDZ were in many
cases not concentration-dependent, probably for its
multi-target actions [27, 28]. Additional factors, such as
feedback mechanisms, changes in receptor expression
and receptor desensitisation/internalisation may occur.
To investigate the contribution of TDZ on astrocyte
metabolism, lactate release was analysed. Glucose is me-
tabolized to lactate by astrocytes and is then released
into the extracellular space and oxidized by neurons to
meet part of their energy needs [56]. In the experimental
model of inflammation, LPS-TNF-α significantly de-
creased the amount of lactate in the culture media; TDZ
challenge for 72 h before inflammation induction com-
pletely reversed this effect, suggesting that the protective
effects of TDZ on activated astrocytes may involve
changes in cell metabolism too. Consistent with our
data, it has been reported that exposure of murine astro-
cytes to pro-inflammatory cytokines decreased lactate
release in response to glutamate stimulation [72].
Gavillet and colleagues have concluded that a pro-
inflammatory environment, such as that present in
Alzheimer’s disease or depression, markedly modifies
the metabolic phenotype of astrocytes, increasing
a
b
Fig. 9 Contribution of 5-HTR receptors in TDZ-elicited cyto-protective
effects. a Human astrocytes were pre-treated with medium alone
(control), or 15 nM (S)-WAY 100135 (5-HT1AR antagonist), or 30 nM
(R)-DOI, or 250 nM clonidine (α-AR agonist), or 100 μM histamine (H1
histamine receptor agonist). After 15 min, cells were incubated with TDZ
(10 μM) for 72 h, followed by LPS-TNF-α for an additional 24 h. b Human
astrocytes were pre-treated with medium alone (control), or 15 nM
(S)-WAY 100135 (5-HT1AR antagonist), or 10 nM GR 127935 (5-HT1B/DR
antagonist), or 5 nM RS 127445 (5-HT2BR antagonist), or 30 nM (R)-DOI or
100 nM SR 57227 (5-HT3R agonist). After 15 min, cells were incubated
with FLUOX (10 μM) for 72 h, followed by LPS-TNF-α for an additional
24 h. At the end of treatments, cell proliferation was measured using
MTS assay. The data are expressed as percentage with respect to
untreated cells (control), set to 100 %, and are the mean ± SEM of three
independent experiments, each performed in triplicate. The significance
of the differences was determined using a one-way ANOVA-Tukey HSD
post hoc test: **P< 0.01, ***P< 0.001 vs. control; #P< 0.05, ##P< 0.01,
###P< 0.001 vs cells treated with LPS-TNF-α; §§P< 0.01, §§§P< 0.001 vs
cells treated with TDZ-LPS-TNF-α (a) or FLUOX-LPS-TNF-α (b)





Fig. 10 TDZ modulation of the ERK1/2 pathway. a, b Astrocytes were treated with medium alone (basal), or with the indicated concentrations of TDZ,
or FLUOX (10 μM) or 5-HT (10 μM)for 30 min (a) or 24 h (b). Following incubation, the levels of phosphorylated and total ERK1/2 were evaluated using
an ELISA kit as described in the Methods section. The data are expressed as phosphorylated/total ERK1/2 ratio. The data are the mean ± SEM of three
independent experiments performed in triplicate. c Cells were pre-incubated with medium alone (basal), or 15 nM (S)-WAY 100135 (5-HT1AR antagonist), or
30 nM (R)-DOI (5-HT2A/CR agonist), or 250 nM clonidine (α-adrenergic receptor agonist), or 100 μM histamine (H1 histamine receptor agonist). After 15 min,
cells were incubated with TDZ (10 μM) for an additional 30 min. d Human astrocytes were pre-treated with medium alone (basal), or 15 nM (S)-WAY
100135 (5-HT1AR antagonist), or 10 nM GR 127935 (5-HT1B/DR antagonist), or 5 nM RS 127445 (5-HT2BR antagonist), or 30 nM (R)-DOI (5-HT2A/CR agonist) or
100 nM SR 57227 (5-HT3R agonist). After 15 min, cells were incubated with FLUOX (10 μM) for an additional 30 min. Following incubation, the levels of
phosphorylated and total ERK1/2 were evaluated using an ELISA kit. e Human astrocytes were pre-treated with 200 ng/ml PTX (Gαi/o inhibitor), 1 μM H89
(PKA inhibitor), or 1 μM bisindolylmaleimide (PKC inhibitor), or 500 nM wortmannin (PI3K inhibitor); then, cells were incubated with TDZ (10 μM) or FLUOX
(10 μM) for an additional 30 min. Following incubation, the levels of phosphorylated and total ERK1/2 were evaluated using an ELISA kit. The significance
of the differences was determined using a one-way ANOVA-Tukey HSD post hoc test: *P< 0.05, **P< 0.01 ***P< 0.01 vs. basal; ##P< 0.01, ###P< 0.001 vs
cells stimulated with TDZ or FLUOX





Fig. 11 TDZ modulation of the AKT pathway. a, b Astrocytes were treated with medium alone (basal), or with the indicated
concentrations of TDZ, or FLUOX (10 μM) or 5-HT (10 μM) for 30 min (a) or 24 h (b). Following incubation, the levels of phosphorylated
and total AKT were evaluated using an ELISA kit as described in the Methods section. The data are expressed as phosphorylated/total
AKT ratio. The data are the mean ± SEM of three independent experiments performed in triplicate. c Cells were pre-incubated with
medium alone (basal), or 15 nM (S)-WAY 100135 (5-HT1AR antagonist), or 30 nM (R)-DOI (5-HT2A/CR agonist), or 250 nM clonidine (α-AR
agonist), or 100 μM histamine (H1 histamine receptor agonist). After 15 min, cells were incubated with TDZ (10 μM) for an additional
30 min. d Human astrocytes were pre-treated with medium alone (basal), or 15 nM (S)-WAY 100135 (5-HT1AR antagonist), or 10 nM GR
127935 (5-HT1B/DR antagonist), or 5 nM RS 127445 (5-HT2BR antagonist), or 30 nM (R)-DOI (5-HT2A/CR agonist) or 100 nM SR 57227 (5-HT3R agonist).
After 15 min, cells were incubated with FLUOX (10 μM) for an additional 30 min. Following incubation, the levels of phosphorylated and total AKT were
evaluated using an ELISA kit. e Human astrocytes were pre-treated with 200 ng/ml PTX (Gαi/o inhibitor), or 1 μM H89 (PKA inhibitor), or 1 μM
bisindolylmaleimide (PKC inhibitor); then, cells were incubated with TDZ (10 μM) or FLUOX (10 μM) for an additional 30 min. Following incubation, the
levels of phosphorylated and total AKT were evaluated using an ELISA kit. The significance of the differences was determined using a one-way
ANOVA-Tukey HSD post hoc test: *P < 0.05, **P < 0.01, ***P < 0.001 vs. basal; #P < 0.05, ##P < 0.01 vs cells stimulated with TDZ or FLUOX





Fig. 12 TDZ modulation of the JNK pathway. a, b Astrocytes were treated with medium alone (basal), or with the indicated concentrations of
TDZ, or FLUOX (10 μM) for 30 min (a) or 24 h (b). Following incubation, the levels of phosphorylated and total JNK were evaluated using an
ELISA kit as described in the Methods section. The data are expressed as phosphorylated/total JNK ratio. The data are the mean ± SEM of three
independent experiments performed in triplicate. c Cells were pre-incubated with medium alone (basal), or 15 nM (S)-WAY 100135 (5-HT1AR
antagonist), or 30 nM (R)-DOI (5-HT2A/CR agonist), or 250 nM clonidine (α-AR agonist), or 100 μM histamine (H1 histamine receptor agonist). After
15 min, cells were incubated with TDZ (10 μM) for an additional 30 min. d Human astrocytes were pre-treated with medium alone (basal), or 15
nM (S)-WAY 100135 (5-HT1AR antagonist), or 10 nM GR 127935 (5-HT1B/DR antagonist), or 5 nM RS 127445 (5-HT2BR antagonist), or 30 nM (R)-DOI
(5-HT2A/CR agonist) or 100 nM SR 57227 (5-HT3R agonist). After 15 min, cells were incubated with FLUOX (10 μM) for an additional 30 min.
Following incubation, the levels of phosphorylated and total JNK were evaluated using an ELISA kit. e Human astrocytes were pre-treated
with 1 μM H89 (PKA inhibitor), or 1 μM bisindolylmaleimide (PKC inhibitor); after 15 min, cells were incubated with TDZ (10 μM) or FLUOX
(10 μM) for an additional 30 min. Following incubation, the levels of phosphorylated and total JNK were evaluated using an ELISA kit. The
significance of the differences was determined using a one-way ANOVA-Tukey HSD post hoc test: *P < 0.05, **P < 0.01, ***P < 0.001 vs. basal;
#P < 0.05, ##P < 0.01, ###P < 0.001 vs cells stimulated with TDZ or FLUOX
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neuronal vulnerability through disrupted energy me-
tabolism and increased hydrogen peroxide release [72].
In this respect, the increased lactate release by cortical
astrocytes in response to FLUOX has been suggested
to contribute to protect neurons from stress [73] and
to normalize hypometabolism in the prefrontal cortex
of depressed patients [73, 74]. Consistent with this hy-
pothesis and with data reported for paroxetine in
microglial cells [75], our conditioned media experi-
ments showed that TDZ significantly relieved activated
astrocyte-mediated neurotoxicity.
Using selective agonists/antagonists, TDZ was demon-
strated to exert its cyto-protective effects through its
agonism at 5-HT1ARs and its antagonism at 5-HT2A/
CRs. In contrast, FLUOX showed to act through the acti-
vation of 5-HT2BRs. SSRI effects exerted via the 5-
HT2BR had previously been described not only in cul-
tured neurons [76] but also in cultured astrocytes [58];
in particular, this 5-HTR subtype seems to be indispens-
able for the anti-depressant action of FLUOX [58, 77].
The putative contributions of ERKs, AKT and JNK
were then assessed after 30-min and 24-h TDZ treat-
ment, in order to get insight on the receptors involved
in the observed effects.
Consistent with literature data [64, 78], FLUOX sig-
nificantly activated ERK1/2 by a 5-HT2BR-mediated
mechanism. Surprisingly, TDZ inhibited basal ERK activ-
ity, via activation of 5-HT1ARs and blockage of 5-HT2A/
CRs (Fig. 14). 5-HT1ARs couple to inhibitory G-proteins,
resulting in decreased cAMP production and PKA activ-
ity [79], but the regulation of ERK activity by these re-
ceptors in brain is divergent and complicated [80].
Consistent with our finding, some papers have reported
5-HT1AR activation decreases ERK phosphorylation in
the hippocampus [81–83]. The TDZ-mediated decrease
of ERK suggests that this anti-depressant modulates
CREB and BDNF transcription via a different, ERK-
independent, mechanism. Consistent with this hypoth-
esis, TDZ enhancement of CREB and BDNF mRNA
levels was counteracted by a PI3K inhibitor. Similarly,
a b
c d
Fig. 13 Modulation of the ERK1/2 and JNK pathways in an experimental model of inflammation. Human astrocytes were treated with medium
alone (basal), or the indicated concentrations of TDZ, or FLUOX (10 μM) for 24 h (a, c) or 72 h (b, d); after drug removal, cells were incubated
with LPS-TNF-α for an additional 24 h. Following incubation, levels of phosphorylated and total ERK 1/2 or JNK were evaluated using an ELISA kit
as described in the Methods section. The data were calculated as percentages of phosphorylated or total ERK1/2 or JNK relative to untreated cells
(basal), which were set at 100 %, and are expressed as phosphorylated/total ERK1/2 (a, b) or JNK (c, d) ratio. The data are the mean ± SEM of three
independent experiments performed in triplicate. The significance of the differences was determined using a one-way ANOVA-Tukey HSD post
hoc test: *P < 0.05, **P < 0.01, ***P < 0.001 vs. control; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. cells treated with LPS-TNF-α
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an involvement of PI3K in BDNF promoter activation
and in the related CREB transcription has been re-
ported also for other mood stabilizers, such as lithium
or valproate [84–86]. Moreover, melatonin has been
demonstrated to modulate CREB and GDNF expression
in primary astrocytes by a PI3K/AKT mechanism [87].
Consistent with PI3K involvement in TDZ-mediated
effects, the drug showed to modulate the downstream
effector of PI3K and AKT. Whereas FLUOX activated
AKT via 5-HT2BRs transactivation of epidermal growth
factor receptor [88], TDZ enhanced AKT phosphorylation
mainly involving 5-HT1ARs (Fig. 14). Consistent with our
findings, few papers have shown a Gi/o and PI3K sensitive
regulation of AKT by 5-HT1ARs [89, 90].
AKT pathway may be involved in TDZ-elicited effects
on astrocyte metabolism: as reported for 5-HT and
FLUOX [60, 80, 91, 92], activated AKT inhibits
glycogensynthasekinase-3(GSK3) [93], thus leading to
stimulation of glycogen synthesis and to up-regulation of
glucose metabolism. Whereas FLUOX regulation of
Fig. 14 The possible intracellular route of TDZ in human astrocytes. Schematic overview of the possible TDZ/ERK/AKT/JNK signalling pathways in our
experimental model is depicted. In astrocytes, the 5-HT1AR is coupled to Gαi/o proteins [83]; its activation by TDZ decreases ERK phosphorylation via
Gαi/o protein ([a]) [84, 85], and increases AKT phosphorylation ([b]) [92, 93]. The PI3K/AKT pathway may contribute to deregulate JNK. Moreover, AKT
phosphorylates GSK3, blocking in turn its activity, leading to alteration of astrocyte metabolism ([c]) [92, 93]. TDZ enhances CREB and
BDNF transcription via a PI3K/AKT pathway ([d]). 5-HT2A/CRs may couple to Gαq proteins [40]; TDZ, showing an antagonistic activity on
5HT2A/CRs, may reduce ERK activation ([e]). TDZ antagonizes α-ARs ([f]), contributing to reduce JNK phosphorylation. Abbreviations: AC:
adenylyl cyclase; cAMP: cyclic adenosine monophosphate; PKA: protein kinase A; PKC: protein kinase C; CREB: cAMP response element-binding protein;
BDNF: brain-derived nerve factor; ERK: extracellular signal-regulated kinase; PI3K: phosphatidylinositol-4,5-bisphosphate 3-kinase; GSK3: glycogen
synthase kinase 3; PDK1: 3-phosphoinositide dependent protein kinase-1; JNKs: c-Jun N-terminal kinases; PLC: Phospholipase C; PIP2: phosphatidylinositol
4,5-bisphosphate; IP3: inositol trisphosphate; DAG: diacyl-glycerol
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astrocyte metabolism mainly implicates 5-HT2BRs, an
involvement of 5-HT1ARs can be speculated in the case
of TDZ, on the light of experimental data showing that
5-HT1ARs have a major role in mediating the AKT-
dependent GSK3-regulation [93].
Finally, TDZ, as well as FLUOX, inhibited the constitutive
phosphorylation of JNKs (Fig. 14), suggesting that these
kinases may function in the effects of anti-depressant under
physiological conditions. Consistent with JNK’s role in
apoptosis, brain injury and depression [25, 67, 94], when
human astrocytes were incubated with LPS-TNF-α, a sig-
nificant increase in phosphorylated JNK was observed.
Similar to the effects of paroxetine in LPS-activated micro-
glia reported by Liu [75], TDZ strongly decreased ERK
baseline activity in activated astrocytes.
Conclusions
In summary, the effect of TDZ on astrocytes under both
physiological condition and inflammatory insult has
been determined. This study has shown that TDZ alone:
1. decreased the cellular release of the
pro-inflammatory cytokine IFN-γ;
2. increased the mRNA expression of neurotrophic and
transcription factors;
3. enhanced lactate release;
4. activated AKT mainly through 5-HT1AR stimulation;
5. inhibited ERK1/2 and JNK constitutive
phosphorylation through 5-HT1AR stimulation,
5-HT2A/CR blockage or α-AR antagonism.
Most importantly, a pre-treatment with TDZ before
the inflammatory insult:
1. completely reversed the decrease of cell proliferation,
through a mechanism that involved an activation of
5-HT1ARs and an antagonism at 5-HT2A/CRs;
2. counteracted the decrease of lactate release
mediated by LPS-TNF-α;
3. significantly relieved activated astrocyte-mediated
neurotoxicity;
4. inhibited inflammation-induced production of
inflammatory mediators, such as IL-6 and IFN-γ
production in LPS-TNF-α stimulated astrocytes;
5. counteracted the decrease of neurotrophic and
transcription factors mediated by LPS-TNF-α after
72 h;
6. counteracted the activation of ERK1/2 and JNK
elicited by LPS-TNF-α.
The results at the molecular level, as summarised in
the schematic diagram (Fig. 14), demonstrate that TDZ
might help normalize trophic and metabolic support to
neurons in neuroinflammation, which has been associated
with neurological diseases, including major depression.
Moreover, these results indicate a potential role for TDZ
in neuro-protection via its anti-neuroinflammatory effects
in addition to its use in depression.
Additional files
Additional file 1: Figure S1. Human astrocytes were treated with
different concentrations of TDZ for seven days. At the end of treatment,
cell proliferation was measured by MTS assay. The data are expressed as
percentages relative to untreated cells (control), which were set at 100 %,
and represent the mean ± SEM of three independent experiments, each
performed in triplicate. Statistical significance was determined using a
one-way ANOVA-Tukey post hoc test. (PDF 81 kb)
Additional file 2: Figure S2. Human astrocytes were treated with
medium alone (basal), or 10 μM TDZ, or 10 μM FLUOX for 30 min.
Following incubation, levels of phosphorylated and total ERK 1/2 were
evaluated by western blot analysis. (A) Representative western blots. (B)
Densitometric analysis of the immunoreactive bands was performed
using ImageJ. The data are expressed as the percentage of optical density of
the immunoreactive band relative to that of the control, which was set at
100 %, and are the mean values ± SEM of two different experiments. Statistical
significance was determined using a one-way ANOVA-Tukey HSD post hoc
test: **P< 0.01, ***P< 0.001 vs. control. (PDF 205 kb)
Additional file 3: Figure S3. Human astrocytes were pre-treated with
500 nM wortmannin (PI3K inhibitor) or 5 μM PD98059 (MEK1 inhibitor);
after 30 min, cells were incubated with TDZ (100 nM) FLUOX (10 μM) for
an additional 24 h. At the end of treatment, total RNA was extracted, and
relative mRNA quantification of CREB and BDNF was performed by real-time
RT-PCR. The data are expressed as fold changes vs. control and represent
the mean ± SEM of three different experiments, each performed in
duplicate. Statistical significance was determined using a one-way ANOVA-
Tukey HSD post hoc test: **P< 0.01 vs. control; ##P< 0.01 vs cells not treated
with the PI3K inhibitor. (PDF 191 kb)
Additional file 4: Figure S4. Human astrocytes were treated with
medium alone (basal), or 10 μM TDZ, or 10 μM FLUOX for 30 min.
Following incubation, levels of phosphorylated and total AKT were
evaluated by western blot analysis. (A) Representative western blots.
(B) Densitometric analysis of the immunoreactive bands was performed
using ImageJ. The data are expressed as the percentage of optical
density of the immunoreactive band relative to that of the control, which
was set at 100 % and are the mean values ± SEM of two different
experiments. Statistical significance was determined using a one-way
ANOVA-Tukey HSD post hoc test: ***P < 0.001 vs. control. (PDF 78 kb)
Additional file 5: Figure S5. Human astrocytes were treated with
medium alone (basal), or 10 μM TDZ, or 10 μM FLUOX for 30 min. Following
incubation, levels of phosphorylated and total JNKs were evaluated by
western blot analysis. (A) Representative western blots. (B) Densitometric
analysis of the immunoreactive bands was performed using ImageJ. The data
are expressed as the percentage of optical density of the immunoreactive
band relative to that of the control, which was set at 100 % and are the mean
values ± SEM of two different experiments. Statistical significance was
determined using a one-way ANOVA-Tukey HSD post hoc test: ***P< 0.001 vs.
control. (PDF 83 kb)
Additional file 6: Figure S6. (A,B) Human astrocytes were transfected
with an ERK-encoding plasmid. Forty h after transfection, ERK overexpression
was verified by western blot, using GAPDH as the loading control. (A)
Representative western blots. (B) Densitometric analysis of the immunoreactive
bands was performed using ImageJ. The data are expressed as the percent-
age of optical density of the immunoreactive band relative to that of the
control (cells transfected with an empty vector), which was set at 100 %,
and are the mean values ± SEM of two different experiments. Statistical sig-
nificance was determined using a one-way ANOVA-Tukey HSD post hoc
test: ***P < 0.001 vs. control. (PDF 165 kb)
Additional file 7: Figure S7. (A,B) Human astrocytes were transfected
with an ERK-encoding plasmid. Forty hours after transfection, cells were
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treated with medium alone (control), different concentrations of TDZ
(1 nM-10 μM) for 72 h; after TDZ removal, cells were incubated with 50 μg/ml
LPS and 50 ng/ml TNF-α for an additional 24 h. At the end of treatments, cell
proliferation was measured using MTS assay. The data are expressed as
percentage with respect to untreated cells (control), set to 100 %, and are the
mean ± SEM of two independent experiments, each performed in triplicate.
The significance of the differences was determined using a one-way ANOVA-
Tukey HSD post hoc test: **P< 0.01, ***P< 0.001 vs. control; ##P< 0.01,
###P< 0.001 vs cells treated with LPS-TNF-α. (PDF 230 kb)
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